@article{f9114e0b662140e5bf9a177095d3a675,
title = "Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression",
abstract = "Background: Digital therapeutics such as cognitive–emotional training have begun to show promise for the treatment of major depressive disorder. Available clinical trial data suggest that monotherapy with cognitive–emotional training using the Emotional Faces Memory Task is beneficial in reducing depressive symptoms in patients with major depressive disorder. The aim of this study was to investigate whether Emotional Faces Memory Task training for major depressive disorder is associated with changes in brain connectivity and whether changes in connectivity parameters are related to symptomatic improvement. Methods: Fourteen major depressive disorder patients received Emotional Faces Memory Task training as monotherapy over a six-week period. Patients were scanned at baseline and posttreatment to identify changes in resting-state functional connectivity and effective connectivity during emotional working memory processing. Results: Compared to baseline, patients showed posttreatment reduced connectivity within resting-state networks involved in self-referential and salience processing and greater integration across the functional connectome at rest. Moreover, we observed a posttreatment increase in the Emotional Faces Memory Task-induced modulation of connectivity between cortical control and limbic brain regions, which was associated with clinical improvement. Discussion: These findings provide initial evidence that cognitive–emotional training may be associated with changes in short-term plasticity of brain networks implicated in major depressive disorder. Conclusion: Our findings pave the way for the principled design of large clinical and neuroimaging studies.",
keywords = "brain plasticity, cognitive training, digital therapeutic, functional magnetic resonance imaging, functional magnetic resonance imaging, major depressive disorder",
author = "Hoch, {Megan M.} and Doucet, {Gaelle E.} and Moser, {Dominik A.} and {Hee Lee}, Won and Collins, {Katherine A.} and Huryk, {Kathryn M.} and DeWilde, {Kaitlin E.} and Lazar Fleysher and Iosifescu, {Dan V.} and Murrough, {James W.} and Charney, {Dennis S.} and Sophia Frangou and Iacoviello, {Brian M.}",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Authors Hoch, Doucet, Moser, Lee, Huryk, DeWilde, Fleysher, and Frangou declare that they have no competing interests. Dr Iacoviello is an adjunct faculty member of the Icahn School of Medicine at Mount Sinai (ISMMS) and is employed full time as the Head of Discovery and Translational Research at Click Therapeutics. Prior to joining Click Therapeutics, Dr Iacoviello (in his role as a full time faculty member at ISMMS) and Dr Charney (Dean of the Icahn School of Medicine at Mount Sinai) codeveloped EFMT as a computer-based brain training exercise for the treatment of depression. Drs Iacoviello and Charney are named coinventors on a patent filed by ISMMS to develop this therapeutic approach as a mobile/remote program (app). There is a licensing agreement between Mount Sinai and Click Therapeutics to develop this technology; if a commercial product is developed, Mount Sinai, Dr Iacoviello, and Dr Charney would benefit financially. Dr Iacoviello has served as a consultant to Fortress Biotech, Inc. and reports grant funding from the National Institutes of Health and the Brain and Behavior Research Foundation. In the past three years, Dr Murrough has provided consultation services to Allergan, Fortress Biotech, Novartis, Janssen Research and Development, Genentech, ProPhase, and Global Medical Education and has received research support from Avanir Pharmaceuticals. In the past five years, Dr Iosifescu has consulted for Avanir, Axome, CNS Response, INSYS Therapeutics, Lundbeck, Otsuka, Servier, and Sunovion, and he has received grant/research support through the Icahn School of Medicine at Mount Sinai from Alkermes, Astra Zeneca, Brainsway, Euthymics, Litecure, Neosync, Roche, and Shire. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institutes of Health grant 5K23MH099223 and the Brain and Behavior Research Foundation (awarding NARSAD Grants) Young Investigator grant #24100, both to B.M.I. Publisher Copyright: {\textcopyright} The Author(s) 2019.",
year = "2019",
doi = "10.1177/2470547019877880",
language = "English",
volume = "3",
journal = "Chronic Stress",
issn = "2470-5470",
publisher = "SAGE Publications Inc.",
}